Cipla

Cipla appoints Shivam Puri as CEO of 'One India Business' from July 1

Homegrown pharma major Cipla Ltd on Tuesday announced the appointment of Shivam Puri as the CEO of its 'One India Business' with effect from July 1, 2026. Puri, currently Managing Director and CEO of Cipla Health Ltd, a wholly-owned subsidiary of the company, has over 23 years of leadership experience across both FMCG and healthcare sectors. He brings strong commercial acumen and consumer-centric expertise, Cipla said in a regulatory filing. He took over as MD and CEO of Cipla Health in 2019, and under his leadership, the company rapidly expanded its portfolio and strengthened its presence across key consumer categories, such as smoking cessation, pain care, cough and cold, skin care, hair care and nutrition, among others, Cipla said. Before joining Cipla Health in 2019, Puri held senior leadership roles at Hindustan Unilever, Jubilant FoodWorks and ITC Ltd, the filing said.

Cipla expands respiratory, specialty manufacturing across India, China, US

Filed 10 applications with USFDA in FY26 to build a pipeline of differentiated products for regulated markets

MedTherapy bets on low-cost CAR-T manufacturing with Noida CDMO push

Boston-headquartered MedTherapy Biotech is expanding its India manufacturing footprint while preparing clinical trials for a lymphoma-focused CAR-T therapy with Cipla

Pace of new product launches, filings key for Cipla's future growth

Strong India and Africa growth partially offset weakness in North America as Cipla focuses on respiratory launches and regulatory filings

Cipla soars 8% despite disappointing Q4; what's driving pharma stock?

Going forward Cipla's management expects to pick up momentum in FY27 and aspires $1 billion revenue from the US itself.

Cipla Q4 profit plunges 55% to ₹554.6 cr amid US drag, higher R&D spend

Drugmaker cites lower contribution from key US products, higher R&D investments and rising operating costs as Q4 FY26 profit declines sharply

Cipla Q4 results: Net profit falls 54.6% to ₹555 crore, revenue drops 2.8%

Total revenue from operations fell 2.8 per cent to ₹6,541 crore, below the average expectations of ₹6,749 crore, hurt by a sales decline in its key North America market

Cipla shares jump 5% after Q4 results; records highest-ever yearly revenue

Cipla reported total income from operations of ₹6,541 crore, down 2.8 per cent year-on-year (Y-o-Y) from ₹6,730 crore in the year-ago period

Q4 results today: Airtel, Oil India, TVS Motors, Cipla, 94 others on May 13

Q4FY26 company results: Firms including ata Motors Commercial Vehicles, Hindustan Petroleum, DLF, and TVS Holdings are also to release their January-March earnings today

Stocks to Watch today: Airtel, Tata Power, Cipla, RVNL, Dixon Tech and more

Stocks to watch today: Jewellery stocks, Tata Power, RVNL, Airtel, Cipla, Dixon Technologies, Dr Reddy's, Berger Paints are among others that will remain in focus today.

Cipla Q4 preview: Profit may plunge on weak US sales; check estimates here

Cipla's March 2026 quarter revenue is expected to decline marginally to ₹6,665 crore as compared to ₹6,730 crore in the year-ago period

Cipla gains US FDA nod for Ventolin; analysts see $100 mn sales potential

Cipla has received the US FDA's approval for generic Ventolin inhaler. Analysts see $100-million sales potential from the drug, which could aid US business outlook

Cipla gets USFDA nod for respiratory issues treatment inhalation aerosol

Pharma major Cipla Ltd on Thursday said it has received final approval from the US health regulator for its generic version of albuterol sulfate inhalation aerosol indicated for the treatment or prevention of bronchospasm. The final approval granted by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of Albuterol sulfate inhalation aerosol of strength 90 mcg per actuation, Cipla said in a regulatory filing. It is the first AB-rated generic therapeutic equivalent of Ventolin HFA, marketed by GlaxoSmithKline, it added. Commenting on the approval, Cipla Managing Director and Global CEO Achin Gupta said, "This marks an important milestone for Cipla and reflects our strong scientific and regulatory capabilities in complex inhalation products." He further said, "Lung health remains at the heart of all our offerings and follows a singular, distilled objective, to build a sustainable and differentiated portfolio for patients globally." Albuter

Pharma cos brace for soft Q4; US drag persists; domestic growth cushions

Pharma sector may see a 7 per cent Y-o-Y growth in reported sales and a 1 per cent increase in Ebitda, led by steady ex-gRevlimid US sales, healthy domestic growth, and favourable forex movements

Trading guide: Nifty eyes 23,200; BSE, Laurus Labs, Cipla on analyst radar

Stocks to buy: Ajit Mishra of Religare Broking recommends buying BSE and Laurus Labs; also suggests Nifty trading strategy

Cipla tanks 20% so far in CY 2026; hits over 2-year low in firm market

Cipla declined 2% to ₹1,195.15, also its lowest level since December 2023 on the BSE in Wednesday's intra-day trade.

Focus on "stock-specific" opportunities: Analyst; suggests 2 stocks to buy

Ajit Mishra of Religare Broking recommends buying Cummins India, Granules and selling Cipla futures; check all details here

Sentiment shift: Earnings upgrade to downgrade ratio improved after Q3

There are hopes of a turnaround in overall corporate earnings after six quarters of single digit growth

Cipla, Kemwell form biologics JV to tap fast-growing biosimilars market

Cipla will hold 60% in the new JV with Kemwell Biopharma, aiming to develop, manufacture and commercialise biologics and biosimilars for global markets amid rising demand

Cipla shares drop 2% after US FDA designates its Greece facility as OAI

Cipla share price fell 2.4 per cent to the day's low of ₹1,335.90 per share on the National Stock Exchange (NSE)